![Virtual Booth](https://www.pharmacompass.com/image/vb/vb-orange-btn.png)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-desktop-headergif-72716.gif)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-mob-headergif-95876.gif)
X
20
Cipla Limited Mumbai In, based in India, is a pharmaceutical company that stands out with its certifications from FDA, EDQM and WHO-GMP.
One of their significant offerings is Olanzapine, supported by a 'Withdrawn by Holder' Certificate of Suitability (CEP) with the number R0-CEP 2015-058 - Rev 00
This Chemical Type CEP, issued on June 17, 2016, remains in force until October 29, 2020, ensuring its reliability within the pharmaceutical industry.
Substance Number 2258 associated with this CEP further emphasizes